Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 21.33% | 27.68% | 16.30% | 7.35% | 14.51% |
| Total Depreciation and Amortization | -6.36% | -0.76% | 4.36% | 8.33% | 7.94% |
| Total Amortization of Deferred Charges | -4.27% | 14.61% | 14.61% | 14.61% | 14.61% |
| Total Other Non-Cash Items | 68.10% | 90.91% | 212.93% | 354.47% | 23.30% |
| Change in Net Operating Assets | -4.59% | 73.14% | -188.77% | -1,123.82% | -562.72% |
| Cash from Operations | 34.58% | 53.10% | 37.10% | 14.24% | 3.40% |
| Capital Expenditure | 41.54% | 84.34% | 81.85% | 86.10% | 82.74% |
| Sale of Property, Plant, and Equipment | 1,742.34% | 1,951.70% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -97.43% | -95.10% | -86.54% | -64.94% | 276.93% |
| Cash from Investing | -97.58% | -95.00% | -86.31% | -63.88% | 358.94% |
| Total Debt Issued | -1.54% | -6.55% | -- | 11,716.03% | -72.93% |
| Total Debt Repaid | -8.88% | -17.62% | -32.39% | -52.80% | -64.22% |
| Issuance of Common Stock | 3,209.62% | 2,708.56% | 355.30% | 346.56% | 99.57% |
| Repurchase of Common Stock | -- | -90,500.00% | -90,500.00% | -1,092.11% | 98.28% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 233.57% | 212.19% | 8,594.83% | 9,217.80% | -67.16% |
| Foreign Exchange rate Adjustments | 481.38% | 69.84% | 169.97% | -81.63% | -116.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 427.56% | 219.93% | 49.24% | 24.43% | -313.73% |
